Annual Report

Overview

The report highlights OssDsign's 2025 clinical progress, including an 88.4% fusion rate in the first 108 PROPEL patients and a 100% 24-month TOP FUSION rate. Consolidated group net sales reached 180 159 TSEK, and the company completed a directed share issue of approximately SEK 158 million to support its ScaleToProfit strategy. Its sustainability disclosure assigns oversight of sustainability and compliance policies to the Board and states that the Code of Conduct applies worldwide.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services